BMYMP - Bristol-Myers Squibb's Multiple Myeloma Setback And Other News: The Good Bad And Ugly Of Biopharma
Xenon Pharmaceuticals Reports Financial Results, Misses EPS
Xenon Pharmaceuticals (XENE) reported its fourth quarter and full-year results. While the results were largely impressive, the company missed reaching its revenue and EPS estimates. The company also provided corporate updates about its various activities. For its full year, the company's revenue was at $6.8 million, in comparison to nil revenue it had reported in the year earlier.
Xenon reported spending $38.8 million on its research and development activities during the entire year while it had registered $23.6 million in research and development expenses for the